Aptalis is a privately held, Birmingham, Alabama and Montreal-based, specialty pharmaceutical company that develops, manufactures, markets and distributes a broad line of gastrointestinal (GI) and specialty products, primarily in North America and Europe. Aptalis has manufacturing sites in Canada, Italy, the US, and France.
Aptalis was formed in 2011 after the acquisition of Eurand Pharmaceuticals by Montreal-based Axcan Pharma.
Axcan's traditional focus was on gastrointestinal drugs. Formerly traded publicly on NASDAQ, Axcan was acquired by TPG Capital in 2008. Aptalis continues to be held by TPG.
Eurand Pharmaceuticals was a producer and contract manufacturer of modified release or taste-masked pharmaceutical dosage forms. Eurand's existing manufacturing facilities in Vandalia, Ohio and Milan, Italy continue to operate under the Aptalis name.